Renocis Pharmaceuticals Private Limited
About Renocis Pharmaceuticals Private Limited
Data last updated:
Renocis Pharmaceuticals Private Limited is a private limited company based in Jaipur, Rajasthan, India. It operates in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 26 August 2013 and has been in existence for over 13 years.
The company is registered with the Registrar of Companies (ROC), Jaipur, under CIN U24232RJ2013PTC043579. Its GSTIN is 08AAGCR5597N1ZG (Rajasthan).
The company has an authorised share capital of ₹25 Lakh and a paid-up capital of ₹15 Lakh. It is led by directors Anil Agarwal and Arvind Sharma.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at B – 58A Path No. 8 Jamuna Nagar Sodala, Jaipur, Rajasthan, India – 302006.
As per the financials filed for FY 2025, the company reported a revenue of ₹6.74 Cr, a growth of 1% compared to the previous year. For the same year it recorded a net profit of ₹17.02 Lakh (net margin 2.5%) and EBITDA of ₹36.31 Lakh (EBITDA margin 5.4%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 11% over five years.
The company has 1 deal on record (1 rights issue); the latest was in November 2014.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Renocis Pharmaceuticals Private Limited's registered office is in Jaipur, Rajasthan. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressB – 58A Path No. 8 Jamuna Nagar Sodala, Jaipur, Rajasthan, India – 302006
- IndustryTrading, Wholesale, Other Wholesale
To see the full contact details of Renocis Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Renocis Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Renocis Pharmaceuticals Private Limited, buy the company report.
Financials of Renocis Pharmaceuticals Private Limited
FY 2025 filings availableRenocis Pharmaceuticals Private Limited reported revenue of ₹6.74 Cr (up 1% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 11% over five years, including 1% growth in the latest year. EBITDA rose 12% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹36.31 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹17.02 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.4% | ||||
| Net Profit Margin | 2.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Renocis Pharmaceuticals Private Limited, buy the company report.
Board of directors of Renocis Pharmaceuticals Private Limited
Renocis Pharmaceuticals has 2 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anil Agarwal | Director | 15 Dec 2016 | 9 Years 10 Months | Current |
| Arvind Sharma | Director | 10 Oct 2024 | 2 Years 0 Months | Current |
Auditor
Renocis Pharmaceuticals Private Limited is audited by PAWAN CHANDRA GOYAL AND COMPANY for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PAWAN CHANDRA GOYAL AND COMPANY | FY 2017 | 011038C |
Shareholding
The shareholding of Renocis Pharmaceuticals Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Renocis Pharmaceuticals Private Limited, buy the company report.
Deals & funding
Renocis Pharmaceuticals Private Limited has 1 deal on record (1 rights issue); the latest was in November 2014.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2014 | Rights issue | ₹14 Lakh | Investors: 3 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Renocis Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Renocis Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Renocis Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 08AAGCR5597N1ZG | Rajasthan | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Renocis Pharmaceuticals Private Limited, buy the company report.
Recent activity
Renocis Pharmaceuticals Private Limited has 9 board changes on record since 2013: 2 appointments and 7 cessations. The latest: Anjana Sharma ceased to be Director on 15 Oct 2024.
Frequently asked questions
Renocis Pharmaceuticals is an active private limited company based in Jaipur, Rajasthan, India. The company works in wholesale, within the trading industry. It was incorporated on 26 August 2013 (13+ years old) and is registered under CIN U24232RJ2013PTC043579.
Renocis Pharmaceuticals has 2 current directors:
- Anil Agarwal - Director
- Arvind Sharma - Director
The latest financial statements of Renocis Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Renocis Pharmaceuticals is 08AAGCR5597N1ZG, registered in Rajasthan.
The CIN (Corporate Identification Number) of Renocis Pharmaceuticals is U24232RJ2013PTC043579. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Renocis Pharmaceuticals was incorporated on 26 August 2013, making it 13+ years old. It is registered with the Registrar of Companies, Jaipur.
Renocis Pharmaceuticals has 1 deal on record (1 rights issue); the latest was in November 2014.
Anjana Sharma ceased to be Director on 15 Oct 2024. Shashi Agrawal ceased to be Director on 15 Oct 2024. Arvind Sharma was appointed as Director on 10 Oct 2024. Renocis Pharmaceuticals has 9 board changes on record in total.
The registered office of Renocis Pharmaceuticals is at B – 58A Path No. 8 Jamuna Nagar Sodala, Jaipur, Rajasthan, India – 302006.
Renocis Pharmaceuticals operates in the trading industry, in the wholesale segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
